CDXC News and Press, ChromaDex Corporation

ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD + ) research with a focus on healthy aging, announced that it will hold a conference call on Wednesday, August 7, 2024 at 4:30 p.m. ET to discuss its financial results for the second quarter, which...

Results from the at-home test kit are available to HCPs and their patients through 1health ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, launches the Niagen+ NAD+ Test Kit *, now available ...

ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD + ) research with a focus on healthy aging, announces the appointment of Carlos Lopez as Senior Vice President, General Counsel. Mr. Lopez will oversee the organization's legal function, includ...

2024-07-19 14:40:20 ET More on HSBC Holdings, Otis Worldwide HSBC: Q2 2024 Earnings Preview, Investment Case Remains Geared To Income Otis Worldwide: Solid Fundamentals And Growth Levers, But Highly Valued, Hold HSBC: Limited Upside Potential With Some Headwinds (Rat...

2024-07-17 06:39:26 ET More on ChromaDex ChromaDex: Looking To Take The Big Step Into Pharma Seeking Alpha’s Quant Rating on ChromaDex Historical earnings data for ChromaDex Read the full article on Seeking Alpha For further details see: Ch...

U.S. FDA-registered 503B outsourcing facility, Wells Pharma of Houston, will compound and distribute Niagen (nicotinamide riboside chloride) IV and injections to Cenegenics, Clean Market/NutriDrip, Drip Hydration, EXTEN IV, Kensho Wellbeing, The NAD MD, Next Health, The Remedy Room, Restore Hyper...

2024-07-01 08:39:20 ET More on ChromaDex ChromaDex: Looking To Take The Big Step Into Pharma ChromaDex Q1 2024 Earnings Preview Seeking Alpha’s Quant Rating on ChromaDex Historical earnings data for ChromaDex Read the full article on Seeking ...

ChromaDex continues to drive innovation and growth with its proprietary Tru Niagen ® supplement, backed by strong financial performance and a robust intellectual property portfolio ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD +...

2024-06-26 12:20:23 ET Summary ChromaDex Corporation is a leader in NAD+ development for healthy aging with Tru Niagen, showing strong growth and attractive valuation. ChromaDex is making a move into the pharma industry with NRC candidate for AT, receiving FDA designations and pre...

NR improved the six-minute walking distance and treadmill walking time for those with PAD ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD + ) research, shares results from a milestone phase II clinical study showcasing the promising effe...